GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

A Study to Evaluate the Effect of the Transient Receptor Potential Vanilloid 4 (TRPV4) Channel Blocker, GSK2798745, on Pulmonary Gas Transfer and Respiration in Patients With Congestive Heart Failure

Phase 2

Completed

Conditions: Heart Failure

Interventions: Drug: GSK2798745
Drug: Placebo

First Posted Date: 2015-07-15

Last Posted Date: 2018-09-05

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 11

Registration Number: NCT02497937

Locations: 🇺🇸
GSK Investigational Site, Rochester, Minnesota, United States

A Study to Determine Bioequivalence of Isotretinoin in Healthy Male Subjects Under Fed Condition

Phase 1

Completed

Conditions: Acne Vulgaris

First Posted Date: 2015-07-15

Last Posted Date: 2017-06-12

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 36

Registration Number: NCT02498288

Locations: 🇲🇽
GSK Investigational Site, Monterrey, Nuevo León, Mexico

A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Albiglutide 50 mg
Drug: Placebo
Drug: CCK (Kinevac)

First Posted Date: 2015-07-14

Last Posted Date: 2018-04-05

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 20

Registration Number: NCT02496221

Locations: 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States

A Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' RSV Investigational Vaccine (ChAd155-RSV) (GSK3389245A) in Healthy Adults

Phase 1

Completed

Conditions: Respiratory Synctial Virus Infections

Interventions: Drug: Placebo
Biological: GSK3389245A_LD GROUP
Biological: GSK3389245A_HD GROUP
Biological: Bexsero

First Posted Date: 2015-07-08

Last Posted Date: 2018-08-20

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 73

Registration Number: NCT02491463

Locations: 🇬🇧
GSK Investigational Site, Oxford, Oxfordshire, United Kingdom

Burden of Herpes Zoster and Post-herpetic Neuralgia Among People ≥ 50 Years Old in France

Completed

Conditions: Herpes Zoster

Interventions: Other: Data collection

First Posted Date: 2015-07-01

Last Posted Date: 2019-09-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 106

Registration Number: NCT02487472

A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults

Phase 2

Completed

Conditions: Virus Diseases

Interventions: Biological: GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)
Drug: Placebo